Treatment: Immunomodulatory drugs and rituximab

P. A. Hart; S. T. Chari

doi:10.1007/978-3-642-55086-7_23

Treatment: Immunomodulatory drugs and rituximab

P. A. Hart, S. T. Chari

Gastroenterology and Hepatology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Autoimmune pancreatitis (AIP) is the pancreatic manifestation of the multiorgan syndrome currently referred to as IgG4-related disease (IgG4-RD). Although AIP and the other organ manifestations of IgG4-RD characteristically respond to steroid treatment, a subset of individuals has disease that is difficult to control, including those who are unable to tolerate high-dose steroids, develop steroid dependence, or have frequent relapses despite maintenance treatment. Existing data suggest that immunomodulatory agents and rituximab (RTX) may be helpful for some to achieve and maintain remission; however, additional studies demonstrating efficacy are needed.

Original language	English (US)
Title of host publication	Autoimmune Pancreatitis
Publisher	Springer Berlin Heidelberg
Pages	155-160
Number of pages	6
ISBN (Electronic)	9783642550867
ISBN (Print)	9783642550850
DOIs	https://doi.org/10.1007/978-3-642-55086-7_23
State	Published - Jan 1 2015

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-642-55086-7_23

Cite this

@inbook{8baf576f2bd1465687d8fe5c1488d6dd,

title = "Treatment: Immunomodulatory drugs and rituximab",

abstract = "Autoimmune pancreatitis (AIP) is the pancreatic manifestation of the multiorgan syndrome currently referred to as IgG4-related disease (IgG4-RD). Although AIP and the other organ manifestations of IgG4-RD characteristically respond to steroid treatment, a subset of individuals has disease that is difficult to control, including those who are unable to tolerate high-dose steroids, develop steroid dependence, or have frequent relapses despite maintenance treatment. Existing data suggest that immunomodulatory agents and rituximab (RTX) may be helpful for some to achieve and maintain remission; however, additional studies demonstrating efficacy are needed.",

author = "Hart, {P. A.} and Chari, {S. T.}",

note = "Publisher Copyright: {\textcopyright} Springer-Verlag Berlin Heidelberg 2015.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-642-55086-7_23",

language = "English (US)",

isbn = "9783642550850",

pages = "155--160",

booktitle = "Autoimmune Pancreatitis",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Treatment

T2 - Immunomodulatory drugs and rituximab

AU - Hart, P. A.

AU - Chari, S. T.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Autoimmune pancreatitis (AIP) is the pancreatic manifestation of the multiorgan syndrome currently referred to as IgG4-related disease (IgG4-RD). Although AIP and the other organ manifestations of IgG4-RD characteristically respond to steroid treatment, a subset of individuals has disease that is difficult to control, including those who are unable to tolerate high-dose steroids, develop steroid dependence, or have frequent relapses despite maintenance treatment. Existing data suggest that immunomodulatory agents and rituximab (RTX) may be helpful for some to achieve and maintain remission; however, additional studies demonstrating efficacy are needed.

AB - Autoimmune pancreatitis (AIP) is the pancreatic manifestation of the multiorgan syndrome currently referred to as IgG4-related disease (IgG4-RD). Although AIP and the other organ manifestations of IgG4-RD characteristically respond to steroid treatment, a subset of individuals has disease that is difficult to control, including those who are unable to tolerate high-dose steroids, develop steroid dependence, or have frequent relapses despite maintenance treatment. Existing data suggest that immunomodulatory agents and rituximab (RTX) may be helpful for some to achieve and maintain remission; however, additional studies demonstrating efficacy are needed.

UR - http://www.scopus.com/inward/record.url?scp=84956672527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956672527&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-55086-7_23

DO - 10.1007/978-3-642-55086-7_23

M3 - Chapter

AN - SCOPUS:84956672527

SN - 9783642550850

SP - 155

EP - 160

BT - Autoimmune Pancreatitis

PB - Springer Berlin Heidelberg

ER -

Treatment: Immunomodulatory drugs and rituximab

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this